Comparing Two Treatments for Malaria in Senegal
Author Information
Author(s): Ndiaye Jean-Louis A, Faye Babacar, Gueye Ali, Tine Roger, Ndiaye Daouda, Tchania Corinne, Ndiaye Ibrahima, Barry Aichatou, Cissé Badara, Lameyre Valérie, Gaye Oumar
Primary Institution: Université Cheikh Anta Diop, Dakar, Senegal
Hypothesis
Is the efficacy and safety of artesunate plus amodiaquine (ASAQ) non-inferior to artemether plus lumefantrine (AL) for treating recurrent uncomplicated malaria?
Conclusion
Both ASAQ and AL are effective and safe for treating uncomplicated malaria, with ASAQ showing slightly better improvement in hemoglobin levels.
Supporting Evidence
- ACPR rates at day 28 were 98.4% for ASAQ and 96.2% for AL in the intent-to-treat population.
- Treatment-related adverse events were reported in 11.7% of patients, with no significant differences between groups.
- Both treatments showed rapid resolution of fever and elimination of parasites.
Takeaway
This study looked at two malaria treatments to see which one works better. Both treatments helped people get better, but one helped them feel even stronger.
Methodology
A randomized comparative study was conducted in Senegal where patients received either ASAQ or AL for three days, and their responses were monitored.
Potential Biases
No significant bias risks were reported.
Limitations
The study was conducted in a highly seasonal malaria transmission area, resulting in relatively few patients presenting with multiple episodes.
Participant Demographics
Patients included both children and adults with uncomplicated malaria.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI of the difference in ACPR rates for ASAQ and AL was -0.011, 0.056.
Statistical Significance
p = 0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website